化学
细胞毒性
硫酯
大肠杆菌
药理学
毒性
非竞争性抑制剂
生物化学
对接(动物)
部分
肠杆菌科
结构-活动关系
碳酸钙-2
胃肠道
生物活性
肠道菌群
伊立替康
酶抑制剂
铅化合物
G2水电站
作用机理
酶
细胞培养
口服
体外
肠粘膜
抑制性突触后电位
作者
Keren Xu,Zekai Cui,Yingjia Ding,Tao Guo,Jiajia Han,Y Yao,Yue Cai,Bin Wei,Xiaoze Bao,H Chen,Y Q Hua,Qihao Wu,Hong Wang,Zhikun Yang
标识
DOI:10.1021/acs.jmedchem.6c00742
摘要
Gut microbial β-glucuronidase has attracted attention as a potential therapeutic target for mitigating irinotecan (CPT-11)-induced late-onset diarrhea and intestinal injury. Here, we designed and synthesized 60 thioester derivatives bearing a 1,3,4-thiadiazole moiety and evaluated their biological activities. In vitro, 3-5B (IC50 = 0.39 μM) exhibited potent inhibitory activity against Escherichia coliβ-glucuronidase (EcGUS). Kinetic studies showed that 3-5B acts as an uncompetitive EcGUS inhibitor (Ki = 0.60 μM). Furthermore, molecular docking analysis suggested that 3-5B binds EcGUS with high affinity through interactions with residues Asp163, Glu413, and Trp549. Notably, 3-5B showed no inhibitory effect on bovine liver β-glucuronidase, did not inhibit E. coli growth, and exhibited low cytotoxicity toward human Caco-2 cells. In vivo, oral administration of 3-5B (1 mg/kg/d) attenuated CPT-11-induced gastrointestinal toxicity in BALB/cJ mice, including weight loss, diarrhea, and colonic injury. Collectively, these findings identify 3-5B as a promising lead scaffold for the development of EcGUS inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI